Ellipsys Vascular Access System Post Market Surveillance (PS) Study
- Study HIC#:2000030765
- Last Updated:01/01/0001
The proposed clinical study is a prospective, non-randomized, multi-center, single-arm, observational, post-market surveillance (PS) study of the Ellipsys Vascular Access System in subjects eligible for arteriovenous (AV) fistula.
- Age18 years - 80 years
For more information about this study, including how to volunteer, contact:
- Phone Number: 1-203-785-4855
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact email@example.com, or call +18779788343 for more information.
Trial Purpose and Description
The primary objective of this post-market surveillance study is to support the short-term safety of the device and procedure and further assess long-term safety and effectiveness in subjects treated by newly trained providers of the Ellipsys Vascular Access System in the creation of a native AV fistula via percutaneous access in subjects who are on hemodialysis and are medically indicated for the creation of an upper limb anastomosis.
- Male or non-pregnant female ≥ 18 years of age and ≤ 80 years of age
- Life expectancy of at least one year, in the investigator's opinion
- Diagnosed with ESRD or chronic kidney disease on hemodialysis.
- Patients deemed medically eligible for upper extremity autogenous AV fistula creation, per institutional guidelines and/or clinical judgment
- Adequate quality vein based on pre-operative assessment
- Adjacent vein diameter of ≥2.0 mm at target anastomosis site
- Confirmed clinically significant outflow
- Adequate quality radial artery based on pre-operative assessment
a. Arterial lumen diameter of ≥2.0 mm at target anastomosis site
- Adequate collateral arterial perfusion with patent palmar arch as demonstrated by Barbeau Test.
- Radial artery-adjacent vein proximity ≤1.5 mm measured lumen edge-to-lumen edge as determined by pre-procedural ultrasound and confirmed pre-procedure
- Patient is able to provide written informed consent and attend follow-up examinations at the enrolling institution
Imaging-based Inclusion Criteria:
- Confirm radial artery-adjacent vein proximity ≤1.5 mm measured lumen edge-to-lumen edge as determined by pre-procedural ultrasound and confirmed pre-procedurally
- Confirm radial artery and adjacent vein diameter of ≥2.0 mm at target anastomosis site
- Pre-existing ipsilateral vascular disease interfering with the study procedure or potentially confounding the study results including:
- Documented or suspected central venous stenosis (≥ 50%) or
- Upper extremity arterial stenosis or
- Vascular disease at the radial artery / adjacent vein site
- Prior vascular surgery at or proximal (central) to the AVF target site interfering with AVF maturation or other ipsilateral surgery that could potentially confound the study results such as prior axillary dissection or mastectomy
- History of steal syndrome from a previous surgical ipsilateral hemodialysis vascular access which required intervention or abandonment
- Systolic pressures < 100 mg Hg at the time of screening
- Suspected or confirmed skin disease at the skin entry site
- Edema of the upper extremity on the ipsilateral side
- Immunocompromised subjects due to underlying disease or immunosuppressant therapy such as sirolimus (Rapamune®) or Prednisone at a dose of > 10 mg per day
- Known bleeding diathesis, coagulation disorder or medications putting the subject at increased risk, in the Investigator's judgment
- Patients with acute or active infection
- Scheduled kidney transplant within 6 months of enrollment
- Participation in another clinical investigation (excluding retrospective studies or studies not requiring a consent form)
- History of substance abuse or anticipated to be non-compliant with medical care or study requirements based on investigator judgment
- Patient has an active COVID-19 infection or relevant history of COVID-19 (Relevant history of COVID-19 is defined as availability of a positive COVID-19 test with sequela or hospitalization for treatment of COVID-19. Patients with a positive COVID-19 test who were asymptomatic or had mild symptoms may be included if the positive test was more than 6 months prior to enrollment.)